False positive rates of randomized phase II designs

Controlled Clinical Trials

Volumn 20, Issue 4, 1999, Pages 343-352

  Liu, P Y ^a   Leblanc, Michael ^a   Desai, Manisha ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Binary data; Censored survival data; False positive rate; Pick the winner design; Randomized Phase II design

Indexed keywords

ARTICLE; BIOSTATISTICS; HUMAN; PHASE 2 CLINICAL TRIAL; PROBABILITY; RANDOMIZATION; SAMPLE; SURVIVAL RATE;

CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS; SELECTION BIAS; SURVIVAL RATE;

EID: 0033035719     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(99)00009-4     Document Type: Article

References (15)

1. Simon R., Wittes R.E., Ellenberg S.S. Randomized Phase II clinical trials. Cancer Treat Rep. 69:1985;1375-1381.
2. Liu P.Y., Dahlberg S., Crowley J. Selection designs for pilot studies based on survival. Biometrics. 49:1993;391-398.
3. Liu P.Y., Dahlberg S. Design and analysis of multiarm clinical trials with survival endpoints. Control Clin Trials. 16:1995;119-130.
4. Green S., Benedetti J., Crowley J. Clinical Trials in Oncology. 1997;Chapman Hall, London.
5. Gibbons J.D., Okin I., Sobel M. Selecting and Ordering Populations. A New Statistical Methodology:1977;Wiley, New York.
6. Kendall M.G., Stuart A. The Advanced Theory of Statistics Vol 1. 3rd ed:1969;Hafner, New York.
7. Cox D.R. Regression models and life tables. J Roy Stat Soc. 34:1972;187-202.
8. Alberts D.S., Liu P.Y., Hannigan E.V.et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335:1996;1950-1955.
9. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15, 71-85.
10. Kirkwood J.M., Strawderman M.H., Ernstoff M.S.et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma. The Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol. 14:1996;7-17.
11. Lee E.J., George S.L., Amrein P.C.et al. An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia. Results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B Leukemia. 12:1998;139-143.
12. Moore J.O., Dodge R.K., Amrein P.C.et al. Granulocyte colony stimulating factor (Filgrastim) accelerates granulocyte and platelet recovery following intensive post-remission chemotherapy for acute myeloid leukemia with aziridinylbenzoquinone (AZQ) and mitoxantrone. Cancer and Leukemia Group B study 9022 Blood. 89:1997;780-788.
13. Miggia F.M., Liu P.Y., Alberts D.S.et al. Intraperitoneal mitoxantrone or floxuridine. Effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy - A randomized phase II study by the Southwest Oncology Group Gynecol Oncol. 61:1996;395-402.
14. McGuire W.P., Hoskins W.J., Brady M.F.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
15. Flaherty L.E., Liu P.Y., Unger J., Sondak V.K. Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. Am J Clin Oncol. 20:1997;600-604.